Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary NeuroMetrix, Inc. Announces Fourth Quarter 2018 Financial Results Conference Call
WALTHAM, Mass. , Jan. 15, 2019 (GLOBE NEWSWIRE) -- NeuroMetrix , Inc. (NASDAQ: NURO) will issue its fourth quarter 2018 financial results on Thursday morning January 24, 2019 . A conference call will be held shortly afterwards at 8:00 a.m. Eastern. The call may be accessed in the United States at
View HTML
Toggle Summary Quell Named CES 2019 Innovation Awards Honoree
WALTHAM, Mass. , Jan. 08, 2019 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced that it has been named a CES ® 2019 Innovation Awards Honoree for Quell ® 2.0 Wearable Pain Relief Technology™ in the Fitness, Sports and Biotech product category.
View HTML
Toggle Summary NeuroMetrix Adds Artificial Intelligence, Coaching and New Therapy Option to Quell 2.0 For Personalized Pain Relief
The smart wearable harnessing the power of neurostimulation and AI to attack the chronic pain crisis LAS VEGAS, Jan. 07, 2019 (GLOBE NEWSWIRE) -- NeuroMetrix Inc. (Nasdaq: NURO) today unveiled its smartest, smallest and most powerful wearable therapeutic to date.
View HTML
Toggle Summary NeuroMetrix Announces Issuance of New U.S. Patent for Quell Wearable Technology
WALTHAM, Mass. , Dec. 27, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix , Inc. (Nasdaq:NURO) announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No. 10,159,835 titled “Detecting cutaneous electrode peeling using electrode-skin impedance.” The patent covers novel methods of
View HTML
Toggle Summary NeuroMetrix to Present at Upcoming Biotech Showcase 2019 In San Francisco
WALTHAM, Mass. , Dec. 19, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix , Inc. (Nasdaq:NURO) announced today that Shai N. Gozani M.D., Ph.D., President and Chief Executive Officer, will be presenting at the Biotech Showcase 2019 Conference at the Hilton San Francisco Union Square on Monday, January 7 ,
View HTML
Toggle Summary NeuroMetrix Reports Agreement with GSK Healthcare on 2019 Quell Joint Development Program and Modification to Strategic Collaboration
WALTHAM, Mass. , Dec. 11, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix , Inc. (Nasdaq: NURO) today reported momentum in its strategic collaboration with GSK Consumer Healthcare . Under terms of the collaboration entered into in the first quarter of 2018, the parties committed to co-fund future development
View HTML
Toggle Summary NeuroMetrix to Present at the LD Micro 11th Annual Main Event on December 5, 2018
WALTHAM, Mass. , Nov. 28, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix , Inc. (NASDAQ:NURO) today announced that Shai N. Gozani M.D., Ph.D., President and CEO of NeuroMetrix, is scheduled to speak at the upcoming LD Micro Annual Main Event at the Luxe Sunset Bel Air Hotel in Los Angeles, CA. Dr.
View HTML
Toggle Summary NeuroMetrix Announces Issuance of New U.S. Patent for Quell Wearable Technology
WALTHAM, Mass. , Nov. 20, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix , Inc. (Nasdaq:NURO) announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No. 10,130,810 titled “Transcutaneous electrical nerve stimulation with user gesture detector and electrode-skin contact detector,
View HTML
Toggle Summary NeuroMetrix Announces DPNCheck Collaboration Agreement with Fukuda Denshi for Japan Market
WALTHAM, Mass. , Nov. 15, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO), announced today that it had executed a distribution agreement with Fukuda Denshi Co. Ltd. for DPNCheck ® , the Company’s  rapid, point-of-care test for diabetic peripheral neuropathy (DPN).
View HTML
Toggle Summary NeuroMetrix Announces Issuance of New U.S. Patent for Quell Wearable Technology
WALTHAM, Mass. , Oct. 31, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix , Inc. (Nasdaq:NURO) announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No. 10,112,040 titled “Transcutaneous electrical nerve stimulation using novel unbalanced biphasic waveform and novel electrode
View HTML